Sir,

Two recent reports in *The New England Journal of Medicine* on a newly described syndrome, namely TEMPI syndrome (telangiectasia, erythrocytosis, monoclonal paraprotein, paranephric fluid collections, intrapulmonary shunting) are fascinating \[[@bib1], [@bib2]\], considering the number of cases where the radiological finding of perinephric fluid collections are not investigated further \[[@bib3]\] or the concomitant laboratory finding of a paraprotein is dismissed as another case of monoclonal gammopathy of undetermined significance (MGUS). Sykes *et al.* \[[@bib2]\] hypothesize that the IgG paraprotein in TEMPI syndrome may be pathogenic due to the resolution of most clinical features after a trial with the proteasome inhibitor, bortezomib. But, as bortezomib also affects the function of hypoxia-inducible factor-1 alpha (Hif-1α) and down-stream transcription of vascular endothelial growth factor (VEGF) \[[@bib4]\], inhibition of Hif-1α would also explain the resolution of the symptoms seen in the patient described by Sykes *et al.*

Expression of Hif-1α and Hif-1α messenger RNA has been detected in all human tissues \[[@bib5]\]. Intratumoral hypoxia is known to induce Hif-1α expression that increases VEGF and angiogenesis, but growth factors and loss-of-function mutations in von Hippel Lindau gene and p53 also induce Hif-1α expression (and possibly development of telangiectasias and erythrocytosis) \[[@bib6]\]. Zhang *et al.* \[[@bib7]\] showed that even under normoxic conditions, the oncogenic c-Myc/Hif-1α pathway modulates multiple myeloma cell production and mediates production and secretion of VEGF. Bortezomib was also shown to decrease both c-Myc and Hif-1α levels. Specific inhibitors of Hif-1α may therefore reverse most of the pathological manifestations of TEMPI syndrome.
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